Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Tilray

Biotech & Life Sciences · Nanaimo, Canada · Founded 2013 · IPO 2018 Unicorn

Medical cannabis research and production

Valuation
$843M
Market cap · May/2026
Revenue
$821M
Latest reported FY
EBITDA
$61M
Latest reported FY

Investors

1 investor on Tilray's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Privateer Holdings

Global footprint

Where Tilray has talent and traffic

AI talent share
0.3% of workforce is AI talent
(3 of 984 staff)
Core AI00%
Other AI30.3%
Non-AI workforce98199.7%
Workforce by country
14 countries with
team presence
🇨🇦 Canada57.2%
🇺🇸 United States23.5%
🇵🇹 Portugal15.1%
🇦🇺 Australia1%
🇩🇪 Germany1%
Top 5 of 14 shown
Web traffic by country
97K monthly visits
across markets
🇨🇦 Canada44.5%
🇬🇧 United Kingdom29%
🇺🇸 United States14.8%
🇦🇺 Australia3%
🇩🇪 Germany1.9%
Top 5 markets shown

Patent intelligence

$450k patent portfolio · 5 active families

Estimated portfolio value
$450k
0.05% of market cap · 703.5× smaller than top peer BioMarin Pharmaceutical ($317M)
5 active patent families
Where Tilray innovates Cannabis substanceCannabinoidPharmacologyMedicinal chemistryTetrahydrocannabinol

Where Tilray concentrates vs peers

Each axis is a top-10 topic across Tilray and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Tilray's 21 investments and acquisitions.

Every disclosed deal where Tilray appeared as a backer or acquirer, 2018–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

21 deals across Tilray's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Tilray deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Tilray's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        21 of 21 deals

        Market sentiment

        What the market is saying about Tilray

        An AI-synthesized read of the highest-engagement posts about Tilray on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Tilray on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.